PT Medikaloka Hermina (HEAL) investor relations material

Executive summary

• Operates 52 hospitals across 36 cities, focusing on women and children care with a differentiated business model targeting Indonesia's middle class and rising affluence.

• Consolidated financial statements for the year ended December 31, 2025, audited by EY, received an unqualified opinion, confirming fair presentation in accordance with Indonesian Financial Accounting Standards.

• Management asserts responsibility for the accuracy, completeness, and internal controls of the financial statements.

• Achieved revenue growth in FY25 despite low purchasing power, with operational volumes rebounding and higher effective working days.

Financial highlights

• FY25 revenue reached IDR 7,134 billion (Rp7,133,538 million), up 6.2% year-over-year from FY24.

• EBITDA for FY25 was IDR 1,949 billion, with a margin of 27.3%, slightly down from 28.4% in FY24.

• PATMI for FY25 was IDR 536 billion, down 20% year-over-year; net income for the year was Rp548,964 million, down from Rp689,129 million.

• Operating income was Rp967,041 million, compared to Rp1,058,219 million in the prior year.

• Total assets increased to Rp11,887,060 million from Rp10,577,680 million at year-end 2024.

Outlook and guidance

• Maintains a robust credit profile with AA rating reaffirmed in May 2025, supporting future growth and expansion.

• New and revised accounting standards effective in 2026 and 2027 are not expected to have a material impact.

• Management continues to monitor capital structure and plans to maintain a healthy gearing ratio.